Syfovre vs Miebo
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Syfovre | US Miebo | |
|---|---|---|
| Generic name | pegcetacoplan | perfluorohexyloctane |
| Drug class | Complement C3 Inhibitor | Semifluorinated Alkane (Eye Drop) |
| Treats | Geographic atrophy (advanced dry AMD) | Dry eye disease |
| Category | Eye Health | Eye Health |
| Manufacturer | Apellis Pharmaceuticals | Bausch + Lomb |
| Year approved | 2023 | 2023 |
| FDA warning | Moderate warnings | No boxed warning |
| Est. TV ad spend | — | — |
| Common side effects | Eye discomfort, Floaters, Bleeding in the eye, Increased eye pressure | Blurred vision, Eye redness, Temporary discomfort on application |
Frequently asked questions
Is Syfovre or Miebo better?
Neither is universally "better." Syfovre (pegcetacoplan) and Miebo (perfluorohexyloctane) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Syfovre and Miebo?
Syfovre is a Complement C3 Inhibitor made by Apellis Pharmaceuticals, while Miebo is a Semifluorinated Alkane (Eye Drop) made by Bausch + Lomb. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Syfovre has the larger estimated TV advertising budget of the two.